Ole Köhler-Forsberg1, Louisa G Sylvia2, Charles L Bowden3, Joseph R Calabrese4, Michael E Thase5, Richard C Shelton6, Melvin McInnis7, Mauricio Tohen8, James H Kocsis9, Terence A Ketter10, Edward S Friedman11, Thilo Deckersbach2, Michael J Ostacher2, Dan V Iosifescu2, Susan McElroy12, Andrew A Nierenberg2. 1. Department of Clinical Medicine,Aarhus University. 2. Department of Psychiatry,Massachusetts General Hospital,Boston, MA,USA. 3. Department of Psychiatry, University of Texas Health Science Center,San Antonio, TX,USA. 4. Department of Psychiatry, Case Western Reserve University,Cleveland, OH,USA. 5. Department of Psychiatry, University of Pennsylvania,Philadelphia, PA,USA. 6. Department of Psychiatry, University of Alabama at Birmingham,Birmingham, AL,USA. 7. Department of Psychiatry, University of Michigan,Ann Arbor, MI,USA. 8. Department of Psychiatry, University of New Mexico Health Science Center,Albuquerque, NM,USA. 9. Department of Psychiatry, Weill Cornell Medical College,New York, NY,USA. 10. Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine,Stanford, CA,USA. 11. Department of Psychiatry, University of Pittsburgh Medical Center,Pittsburgh, PA,USA. 12. Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine,Cincinnati, OH and Lindner Center of HOPE, Mason, OH,USA.
Abstract
BACKGROUND: Immune system markers may predict affective disorder treatment response, but whether an overall immune system marker predicts bipolar disorder treatment effect is unclear. METHODS: Bipolar CHOICE (N = 482) and LiTMUS (N = 283) were similar comparative effectiveness trials treating patients with bipolar disorder for 24 weeks with four different treatment arms (standard-dose lithium, quetiapine, moderate-dose lithium plus optimised personalised treatment (OPT) and OPT without lithium). We performed secondary mixed effects linear regression analyses adjusted for age, gender, smoking and body mass index to investigate relationships between pre-treatment white blood cell (WBC) levels and clinical global impression scale (CGI) response. RESULTS: Compared to participants with WBC counts of 4.5-10 × 109/l, participants with WBC < 4.5 or WBC ≥ 10 showed similar improvement within each specific treatment arm and in gender-stratified analyses. CONCLUSIONS: An overall immune system marker did not predict differential treatment response to four different treatment approaches for bipolar disorder all lasting 24 weeks.
BACKGROUND: Immune system markers may predict affective disorder treatment response, but whether an overall immune system marker predicts bipolar disorder treatment effect is unclear. METHODS: Bipolar CHOICE (N = 482) and LiTMUS (N = 283) were similar comparative effectiveness trials treating patients with bipolar disorder for 24 weeks with four different treatment arms (standard-dose lithium, quetiapine, moderate-dose lithium plus optimised personalised treatment (OPT) and OPT without lithium). We performed secondary mixed effects linear regression analyses adjusted for age, gender, smoking and body mass index to investigate relationships between pre-treatment white blood cell (WBC) levels and clinical global impression scale (CGI) response. RESULTS: Compared to participants with WBC counts of 4.5-10 × 109/l, participants with WBC &lt; 4.5 or WBC ≥ 10 showed similar improvement within each specific treatment arm and in gender-stratified analyses. CONCLUSIONS: An overall immune system marker did not predict differential treatment response to four different treatment approaches for bipolar disorder all lasting 24 weeks.
Entities:
Keywords:
bipolar disorder; lithium; quetiapine; treatment response; white blood cell
Authors: Cornelis F Vos; Tom K Birkenhäger; Willem A Nolen; Walter W van den Broek; Marieke J H Coenen; Sophie E Ter Hark; Robbert-Jan Verkes; Joost G E Janzing Journal: Brain Behav Immun Health Date: 2021-08-05